Searched for: author%3A%22van+de+Ree%2C+M.A.%22
(1 - 3 of 3)
Tsikas, D. (author), Pham, V.V. (author), Suchy, M.T. (author), van de Ree, M.A. (author), Huisman, M.V. (author), Frölich, J.C. (author), Princen, H.M.G. (author)
The present study describes the effects of atorvastatin on whole body synthesis of nitric oxide (NO), prostacyclin (PGI2), and thromboxane A2 (TxA2), on oxidative stress and nitrite/nitrate-related renal carbonic anhydrase (CA) activity in patients with type 2 diabetes mellitus (T2DM). A double-blind, randomized, placebo-controlled parallel...
article 2015
Alizadeh Dehnavi, R. (author), Beishuizen, E.D. (author), van de Ree, M.A. (author), Le Cessie, S. (author), Huisman, M.V. (author), Kluft, C. (author), Princen, H.M.G. (author), Tamsma, J.T. (author), TNO Kwaliteit van Leven (author)
Background: The burden of cardiovascular disease in diabetes mellitus type 2 (DM2) patients is variable. We hypothesize that metabolic syndrome (MS) and low-grade systemic inflammation modify the extent of atherosclerosis in DM2. Methods: Vascular phenotype was determined using the following endothelium-related, hemostatic, and sonographic...
article 2008
van de Ree, M.A. (author), de Maat, M.P. (author), Kluft, C. (author), Meinders, A.E. (author), Princen, H.M. (author), Huisman, M.V. (author), Gaubius Instituut TNO (author)
BACKGROUND: Patients with Type 2 diabetes mellitus have increased levels of hemostatic risk variables for cardiovascular disease, such as fibrinogen, von Willebrand factor (VWF), factor (F)VIIa, d-dimer and plasminogen activator inhibitor-1 (PAI-1). OBJECTIVES: To evaluate the effect of aggressive vs. standard dose atorvastatin on hemostatic...
article 2003